Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice.
Although Parkinson's disease (PD) is characterized primarily by loss of nigrostriatal dopaminergic neurons, there is a concomitant loss of norepinephrine (NE) neurons in the locus coeruleus. Dopaminergic lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are commonly used to model PD, and although MPTP effectively mimics the dopaminergic neuropathology of PD in mice, it fails to produce PD-like motor deficits. We hypothesized that MPTP is unable to recapitulate the motor abnormalities of PD either because the behavioral paradigms used to measure coordinated behavior in mice are not sensitive enough or because MPTP in the absence of NE loss is insufficient to impair motor control. We tested both possibilities by developing a battery of coordinated movement tests and examining motor deficits in dopamine beta-hydroxylase knockout (Dbh-/-) mice that lack NE altogether. We detected no motor abnormalities in MPTP-treated control mice, despite an 80% loss of striatal dopamine (DA) terminals. Dbh-/- mice, on the other hand, were impaired in most tests and also displayed spontaneous dyskinesias, despite their normal striatal DA content. A subset of these impairments was recapitulated in control mice with 80% NE lesions and reversed in Dbh-/- mice, either by restoration of NE or treatment with a DA agonist. MPTP did not exacerbate baseline motor deficits in Dbh-/- mice. Finally, striatal levels of phospho-ERK-1/2 and DeltaFosB/FosB, proteins which are associated with PD and dyskinesias, were elevated in Dbh-/- mice. These results suggest that loss of locus coeruleus neurons contributes to motor dysfunction in PD.
Rommelfanger
K S
KS
Department of Human Genetics, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.
Edwards
G L
GL
Freeman
K G
KG
Liles
L C
LC
Miller
G W
GW
Weinshenker
D
D
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal; D004299:Dopamine beta-Hydroxylase / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D008125:Locus Coeruleus / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D009043:Motor Activity / Q000187:drug effects*; D009638:Norepinephrine / Q000378:metabolism*; D010641:Phenotype; D010766:Phosphorylation; D016760:Proto-Oncogene Proteins c-fos / Q000235:genetics / Q000378:metabolism; D011954:Receptors, Dopamine / Q000378:metabolism
D016760:Proto-Oncogene Proteins c-fos; D011954:Receptors, Dopamine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004299:Dopamine beta-Hydroxylase; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D009638:Norepinephrine
Biol Psychiatry. 2006 Jan 1;59(1):64-74
16139809
Psychopharmacology (Berl). 2005 Nov;183(1):72-80
16163519
J Neural Transm (Vienna). 2006 Sep;113(9):1119-29
16362627
Neuropsychopharmacology. 2006 Oct;31(10):2221-30
16395294
Brain Res. 2007 Mar 2;1135(1):219-29
17222394
Pharmacol Toxicol. 2000 May;86(5):197-202
10862500
Neuroscience. 2000;101(4):1063-9
11113355
Am J Hum Genet. 2001 Feb;68(2):515-22
11170900
Synapse. 2001 Mar 1;39(3):213-21
11169770
Mov Disord. 2001 Jul;16(4):708-13
11481696
J Neuropathol Exp Neurol. 2002 May;61(5):413-26
12030260
J Neurosci. 2002 Jun 15;22(12):5042-54
12077200
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13873-7
12370425
Exp Neurol. 2002 Nov;178(1):80-90
12460610
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
12498954
J Neural Transm (Vienna). 2003 Feb;110(2):183-200
12589577
Arch Neurol. 2003 Mar;60(3):337-41
12633144
Receptors Channels. 2003;9(5):335-8
14527878
Exp Neurol. 2003 Oct;183(2):418-29
14552882
Neurobiol Dis. 2003 Nov;14(2):218-28
14572444
Exp Neurol. 2003 Nov;184(1):9-13
14637071
Am J Physiol Regul Integr Comp Physiol. 2004 Jan;286(1):R108-13
12969876
Neuroscientist. 2003 Dec;9(6):455-62
14678578
Brain. 2004 Apr;127(Pt 4):888-99
14960500
Brain Res Brain Res Rev. 2004 Apr;45(1):38-78
15063099
Synapse. 2004 Jun 15;52(4):233-44
15103690
Neurobiol Dis. 2004 Jun;16(1):110-23
15207268
J Neurosci. 2004 Oct 20;24(42):9434-40
15496679
J Neurol Sci. 1976 Jun;28(2):147-57
818342
Brain Res Bull. 1983 Jun;10(6):795-804
6616270
Brain Res. 1984 Mar 26;296(1):129-38
6424867
Life Sci. 1985 Jan 21;36(3):201-6
2857048
Brain Res Bull. 1984 Dec;13(6):737-42
6335836
Neurosci Lett. 1985 Oct 24;61(1-2):195-200
3878482
Res Commun Chem Pathol Pharmacol. 1985 Dec;50(3):435-41
3878557
Ann Neurol. 1986 Oct;20(4):449-55
3024555
Neurology. 1987 Jan;37(1):42-6
3796837
Acta Neuropathol. 1988;75(4):370-6
3259063
Res Commun Chem Pathol Pharmacol. 1988 Oct;62(1):93-102
2849789
Neuroscience. 1991;41(2-3):507-23
1870701
Brain Res. 1991 Oct 25;562(2):216-24
1685341
Life Sci. 1992;50(14):995-9
1372673
Adv Neurol. 1993;60:600-8
8380528
Eur J Pharmacol. 1993 Jun 4;236(3):487-9
7689466
Neuroscience. 1993 Sep;56(2):499-511
8247275
Nature. 1995 Apr 13;374(6523):643-6
7715704
J Immunol. 1995 Nov 15;155(10):4613-20
7594460
Cell. 1995 Dec 29;83(7):1197-209
8548806
Funct Neurol. 1997 May-Aug;12(3-4):193-8
9218976
J Neurochem. 1998 Jun;70(6):2468-76
9603211
Brain Res Mol Brain Res. 1998 Jan;53(1-2):41-52
9473580
J Pharmacol Exp Ther. 1997 Oct;283(1):100-7
9336313
J Neural Transm (Vienna). 1998;105(4-5):349-64
9720967
Eur J Pharmacol. 1998 Jul 17;353(1):1-4
9721033
J Neurochem. 1999 Apr;72(4):1625-33
10098870
J Neurochem. 1959 Oct;4:350-2
13840158
J Neurochem. 2004 Dec;91(5):1116-24
15569255
J Neurosci. 2005 Feb 23;25(8):2132-7
15728853
J Neurosci. 2005 Feb 23;25(8):2157-65
15728856
Exp Neurol. 2005 Jul;194(1):66-75
15899244
Lancet Neurol. 2006 Jun;5(6):525-35
16713924